Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Vascular Permeability Factor, Etc.); Or Binds Serum Protein, Plasma Protein, Fibrin, Or Enzyme Patents (Class 424/158.1)
-
Patent number: 10783349Abstract: Techniques are described for determining the quality of a nerve graft by assessing quantitative structural characteristics of the nerve graft. Aspects of the techniques include obtaining an image identifying laminin-containing tissue in the nerve graft; creating a transformed image using a transformation function of an image processing application on the image; using an analysis function of the image processing application, analyzing the transformed image to identify one or more structures in accordance with one or more recognition criteria; and determining one or more structural characteristics of the nerve graft derived from a measurement of the one or more structures.Type: GrantFiled: April 30, 2019Date of Patent: September 22, 2020Assignee: AXOGEN CORPORATIONInventor: Curt Deister
-
Patent number: 10745475Abstract: The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.Type: GrantFiled: September 1, 2014Date of Patent: August 18, 2020Assignee: TAKEDA GMBHInventors: Thomas Wagner, Malin Carlsson, Margit Staum Kaltoft
-
Patent number: 10736900Abstract: The invention relates to a combination of a FGFR inhibitor and an IGF1R inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer. The FGFR inhibitor and the IGFR inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.Type: GrantFiled: March 26, 2015Date of Patent: August 11, 2020Assignee: ASTEX THERAPEUTICS LTDInventors: Eleonora Jovcheva, Timothy Pietro Suren Perera
-
Patent number: 10739352Abstract: A method of diagnosis or prediction of infection of a mammalian wound, said method comprising the step of detecting the presence of a cytokine selected from the group comprising procalcitonin, amino procalcitonin (N-ProCT), eotaxin, granulocyte macrophage colony stimulating factor (GM-CSF), interleukins IB monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1a), regulated upon activation normal T expressed and secreted (RANTES) in fluid taken from the wound. Also claimed is the device for use in the method.Type: GrantFiled: November 20, 2008Date of Patent: August 11, 2020Assignee: CONVATEC TECHNOLOGIES INC.Inventors: Philip Godfrey Bowler, Samantha Alison Jones, Sarah Anne Welsby
-
Patent number: 10729769Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.Type: GrantFiled: September 26, 2019Date of Patent: August 4, 2020Assignee: Fresenius Kabi Deutschland GmbHInventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
-
Patent number: 10696738Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: GrantFiled: February 2, 2017Date of Patent: June 30, 2020Assignee: Glaxon Group LimitedInventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
-
Patent number: 10683368Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and b) the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and c) the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprisiType: GrantFiled: May 4, 2017Date of Patent: June 16, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Ekkehard Moessner, Tilman Schlothauer
-
Patent number: 10683349Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.Type: GrantFiled: February 27, 2018Date of Patent: June 16, 2020Assignee: NOVARTIS AGInventors: Franco E. Di Padova, Thomas Huber, Jean-Michel Rene Rondeau
-
Patent number: 10656153Abstract: Devices, solutions and method capable of quantifying a clinically significant amount of antibodies within a plasma sample obtained from an individual by quantifying binding between antibodies within the sample and microbial proteins are disclosed.Type: GrantFiled: February 23, 2018Date of Patent: May 19, 2020Assignee: PZM DIAGNOSTICS, LLCInventor: Peilin Zhang
-
Patent number: 10640558Abstract: The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.Type: GrantFiled: November 7, 2017Date of Patent: May 5, 2020Assignee: REGENERON PHAMACEUTICALS, INC.Inventors: Jamie M. Orengo, Jeanne Allinne
-
Patent number: 10570199Abstract: The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.Type: GrantFiled: November 18, 2013Date of Patent: February 25, 2020Assignee: KM Biologics Co., Ltd.Inventors: Hiroyuki Shimizu, Miyuki Matsumoto, Kenji Soejima, Masaharu Torikai, Toshihiro Nakashima
-
Patent number: 10526402Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.Type: GrantFiled: February 25, 2016Date of Patent: January 7, 2020Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Alan D'Andrea, Kalindi Parmar, Haojian Zhang
-
Patent number: 10500252Abstract: The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.Type: GrantFiled: June 25, 2014Date of Patent: December 10, 2019Assignee: WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCHInventors: Marc Pellegrini, Gregor Klaus-Peter Ebert, Colin Glenn Begley
-
Patent number: 10478497Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.Type: GrantFiled: July 20, 2017Date of Patent: November 19, 2019Assignee: HYBRIGENICS S.A.Inventors: Susan Benjamin, Cécile Planquette, Rémi Delansorne
-
Patent number: 10472425Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.Type: GrantFiled: May 24, 2017Date of Patent: November 12, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Scott M. Walsh, Daniel B. Dix
-
Patent number: 10464998Abstract: This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.Type: GrantFiled: October 29, 2014Date of Patent: November 5, 2019Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITEDInventors: Yaron Ilan, Meir Mizrahi
-
Patent number: 10441215Abstract: One embodiment includes an image acquisition circuit that accesses a pre-treatment and a post-treatment image of a region of tissue demonstrating non-small cell lung cancer (NSCLC), a segmentation and registration circuit that annotates the tumor represented in the images, and that registers the pre-treatment image with the post-treatment image; a feature extraction circuit that selects a set of pre-treatment and a set of post-treatment quantitative vessel tortuosity (QVT) features from the registered image; a delta-QVT circuit that generates a set of delta-QVT features by computing a difference between the set of post-treatment QVT features and the set of pre-treatment QVT features; and a classification circuit that generates a probability that the region of tissue will respond to immunotherapy based on the difference, and that classifies the region of tissue as a responder or non-responder. Embodiments may generate an immunotherapy treatment plan based on the classification.Type: GrantFiled: February 9, 2018Date of Patent: October 15, 2019Assignee: Case Western Reserve UniversityInventors: Anant Madabhushi, Yuanqi Xie, Vamsidhar Velcheti
-
Patent number: 10426797Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.Type: GrantFiled: March 23, 2018Date of Patent: October 1, 2019Assignees: LENTIGEN TECHNOLOGY, INC., United States of America as Represented by the Secretary, The Dept. of Health and Human ServicesInventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 10408847Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value.Type: GrantFiled: September 20, 2017Date of Patent: September 10, 2019Assignee: SomaLogic, Inc.Inventors: Urs Ochsner, David G. Sterling, Nebojsa Janjic
-
Patent number: 10400035Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.Type: GrantFiled: November 22, 2017Date of Patent: September 3, 2019Assignees: MedImmune, LLC, University of HelsinkiInventors: Kari Alitalo, Simo Syrjala, Karl Lemstrom, Ching Ching Leow, Ronald Herbst, Jane Connor
-
Patent number: 10400036Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.Type: GrantFiled: February 9, 2018Date of Patent: September 3, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Trevor Stitt, Esther Latres
-
Patent number: 10385127Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.Type: GrantFiled: September 13, 2018Date of Patent: August 20, 2019Assignee: NOVARTIS AGInventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
-
Patent number: 10376582Abstract: The invention provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, mannitol, glacial acetic acid, sodium chloride, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.Type: GrantFiled: October 16, 2014Date of Patent: August 13, 2019Assignee: Outlook Therapeutics, Inc.Inventors: John Cini, Athena Nagi, Maria Taddei
-
Patent number: 10376813Abstract: The present invention relates to a method for the determination of chromatography conditions for the separation of a biomolecule from a liquid sample, which method comprises selecting a number of experiments using design of experiments (DoE); performing said experiments with in-line conditioning of orthogonal quality measures; and based on the results from the experiments, determining efficient chromatography conditions for said biomolecule. The invention also relates to a system for performing the method as well as a computer program and an instrument comprising such a computer program.Type: GrantFiled: June 3, 2016Date of Patent: August 13, 2019Assignee: GE HEALTHCARE BIO-SCIENCES ABInventors: Enrique Napoleon Carredano, Gustav Jose Rodrigo
-
Patent number: 10358498Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.Type: GrantFiled: August 11, 2015Date of Patent: July 23, 2019Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company, LimitedInventors: Reimar Abraham, Keisuke Fukuchi, Tanja Lange, Johannes Bange, Ichiro Watanabe, Shinko Hayashi, Toshiaki Ohtsuka
-
Patent number: 10351623Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.Type: GrantFiled: November 20, 2017Date of Patent: July 16, 2019Assignees: Orega Biotech, Institut National de la Sante et de La Recherche Medicale (INSERM)Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
-
Patent number: 10330670Abstract: Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.Type: GrantFiled: October 24, 2013Date of Patent: June 25, 2019Assignees: NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, JAPAN INNOVATION THERAPEUTICS, INC.Inventors: Hiroshi Matsuda, Akane Tanaka
-
Patent number: 10287345Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.Type: GrantFiled: January 6, 2017Date of Patent: May 14, 2019Assignee: Scholar Rock, Inc.Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
-
Patent number: 10273298Abstract: The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives. The compositions are useful for topical administration or for parenteral injection.Type: GrantFiled: July 23, 2014Date of Patent: April 30, 2019Assignee: NOVALIQ GMBHInventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Gesche Graf
-
Patent number: 10259859Abstract: The present disclosure features signal-regulatory protein ? (SIRP-?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.Type: GrantFiled: August 5, 2016Date of Patent: April 16, 2019Assignee: ALX ONCOLOGY INC.Inventors: Jaume Pons, Laura Deming, Corey Goodman, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
-
Patent number: 10189899Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.Type: GrantFiled: July 23, 2014Date of Patent: January 29, 2019Assignee: BIOCON LIMITEDInventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
-
Patent number: 10111953Abstract: The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits elevated serum lipoproteins, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.Type: GrantFiled: May 29, 2014Date of Patent: October 30, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gary Swergold, William J. Sasiela, Robert C. Pordy
-
Patent number: 10081680Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. Antibodies that are bispecific for SIRP? and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.Type: GrantFiled: March 11, 2015Date of Patent: September 25, 2018Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Kipp Andrew Weiskopf, Aaron Michael Ring, Jens-Peter Volkmer, Irving L. Weissman, Nan Guo Ring
-
Patent number: 10059764Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.Type: GrantFiled: January 9, 2015Date of Patent: August 28, 2018Assignee: AnaptysBio, Inc.Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
-
Patent number: 10029016Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.Type: GrantFiled: July 2, 2015Date of Patent: July 24, 2018Assignee: Massachusetts Insitute of TechnologyInventors: Darrell Irvine, Haipeng Liu
-
Patent number: 10023654Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: GrantFiled: December 13, 2016Date of Patent: July 17, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
-
Patent number: 9975945Abstract: The invention relates to a composition comprising immunoglobulins specific to influenza virus and produced through immunization of a producer animal, for use as a medicament for the passive immunization of a human against an infection by an influenza virus, wherein the medicament is administered to the human in at least 1 dose before exposition or risk of exposition to an influenza virus and/or after exposition or risk of exposition to an influenza virus, and wherein the overall amount administered to the human in one or more doses is at least 20 ?g of immunoglobulins per kg body weight. When the composition is for use after exposition or risk of exposition to an influenza virus, it is preferably administered to the human in at least 2 doses after exposition or risk of exposition to an influenza virus.Type: GrantFiled: September 30, 2013Date of Patent: May 22, 2018Assignee: FABENTECHInventors: Bertrand Lepine, Laurent Vacher, Caroline Durand, Cécile Herbreteau-Delale
-
Patent number: 9956244Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.Type: GrantFiled: July 30, 2015Date of Patent: May 1, 2018Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Ji Min Lee, Bo Gyou Kim, Seung Ja Oh, Kyung Ah Kim, Saet Byoul Lee, Jae Woong Hwang
-
Patent number: 9944704Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.Type: GrantFiled: December 19, 2014Date of Patent: April 17, 2018Assignee: Intervet Inc.Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
-
Patent number: 9918822Abstract: A method of stimulating a renal nerve in a human patient comprising, selecting a span of renal artery in the patient for implantation of a self-expanding stent, the artery having a first internal diameter, an artery wall, and being surrounded by peri-adventitial space through which at least one renal nerve extends; measuring the first internal diameter; selecting a self-expanding stent configured to be capable of expanding to have a second diameter that, in an expanded condition once implanted within the artery, is between 2 mm and 4 mm larger than the first diameter; implanting the stent in the span of the renal artery, whereby the stent eventually expands to the second diameter and thereby passes through the artery wall to become embedded in peri-advential space; and at least partially blocking the renal nerve or modulating a function of the nerve.Type: GrantFiled: October 20, 2015Date of Patent: March 20, 2018Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC.Inventors: Chad Abunassar, Erik D. Eli, Denis Tauz
-
Patent number: 9914769Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: July 15, 2014Date of Patent: March 13, 2018Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 9902986Abstract: The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful in delivering a cargo to a bacterium, treating a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, preventing a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, inhibiting the growth of or killing a bacterium, or determining the concentration of a bacterium in a biological sample. In certain embodiments, the bacterium is a Gram-negative bacterium.Type: GrantFiled: October 16, 2014Date of Patent: February 27, 2018Assignee: Massachusetts Institute of TechnologyInventors: Elizabeth Marie Nolan, Tengfei Zheng, Phoom Chairatana
-
Patent number: 9803026Abstract: A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase ? (human PTPRS), or a fragment including an antigen-binding region thereof.Type: GrantFiled: April 27, 2012Date of Patent: October 31, 2017Assignee: SBI Biotech Co., Ltd.Inventors: Tomohide Yamazaki, Jing Zhao, Koji Ishida, Yasue Shibata, Minkwon Cho, Mayuki Endo
-
Patent number: 9690975Abstract: Techniques are described for determining the quality of a nerve graft by assessing quantitative structural characteristics of the nerve graft. Aspects of the techniques include obtaining an image identifying laminin-containing tissue in the nerve graft; creating a transformed image using a transformation function of an image processing application on the image; using an analysis function of the image processing application, analyzing the transformed image to identify one or more structures in accordance with one or more recognition criteria; and determining one or more structural characteristics of the nerve graft derived from a measurement of the one or more structures.Type: GrantFiled: May 28, 2015Date of Patent: June 27, 2017Assignee: AXOGEN CORPORATIONInventor: Curt Deister
-
Patent number: 9683038Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.Type: GrantFiled: September 27, 2012Date of Patent: June 20, 2017Assignee: Novartis AGInventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
-
Patent number: 9650429Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.Type: GrantFiled: February 9, 2015Date of Patent: May 16, 2017Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTYInventor: Suzanne Ostrand-Rosenberg
-
Patent number: 9637543Abstract: Provided herein are antibodies specific for HER3. Also provided are methods of treating cancer in a subject comprising administering an effective amount of the antibodies described herein to the subject.Type: GrantFiled: November 9, 2012Date of Patent: May 2, 2017Assignees: THE UAB RESEARCH FOUNDATION, BEIJING COTIMES BIOTECH CO., LTD.Inventors: Tong Zhou, Donald J. Buchsbaum, Enyun Shen, Xian Chen
-
Patent number: 9598487Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: August 28, 2013Date of Patent: March 21, 2017Assignee: ESBATech, an Alcon Biomedical Unit LLCInventors: Leonardo Jose Borras, David Urech
-
Patent number: 9574004Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.Type: GrantFiled: August 20, 2013Date of Patent: February 21, 2017Assignees: Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc.Inventors: Marius Ardeleanu, Namita A. Gandhi, Neil Graham, Stephanie C. Kirkesseli, Sudeep Kundu, Ross E. Rocklin, Allen Radin, Steven P. Weinstein, Jennifer Davidson Hamilton, Jeffrey Ming
-
Patent number: 9546215Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.Type: GrantFiled: December 9, 2014Date of Patent: January 17, 2017Assignee: ALLAKOS INC.Inventors: Christopher R. Bebbington, Rustom Falahati, Carolina Rita Sousa Fernandes, David John Matthews, Nenad Tomasevic, Jason Williams, John Leung